About Us
Mission
OROCIDIN’s mission is to develop the preferred treatment against aggressive periodontitis. Our innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to provide treatment without exacerbating the pressing concern of antibiotic resistance.
Vision
OROCIDIN’s vision is to revolutionize the treatment of aggressive periodontitis, making it safer, more effective, and efficient to prevent and cure those who are affected by periodontitist. To this end, OROCIDIN will adopt an aggressive sourcing strategy.
Background
Periodontitis is a persistent inflammatory disease that affects the gums and the supporting structures of teeth. While generic antibiotics have traditionally been a standard treatment for periodontitis, the emergence of antibiotic resistance poses a significant challenge to their long-term efficacy. This concern has highlighted the pressing need for the development of new treatment modalities, which can be used either as standalone therapies or in conjunction with existing treatments.
Business Model
Orocidin is committed to developing a new novel drug that is designed to enhance dental procedures, rather than serving as a replacement. A new product, that is likely to be met with a positive response from dental professionals.
Orocidin’s process:
- Establish strategic partnership with a well-established drug delivery company that possesses strong proprietary technology.
- Drug formulation development and pre-clinical tests.
- Generate new intellectual property (IP) rights.
- Commence the initial clinical Proof of Concept (POC)study.
- The anticipated timeline for advancing the development project for periodontitis and establish the global IP rights is approx. 30 months, starting in October 2023.
Strategy
OROCIDIN's strategy for intellectual property and clinical development revolves around forging partnerships with leading global institutions and experts in the domains of IP and periodontitis. Through these collaborations, OROCIDIN aims to generate innovative intellectual property and advance its clinical initiatives, all while remaining closely aligned with the latest research and knowledge in these fields.
Management Team
Allan Wehnert
CEO & Founder
Mr. Wehnert has over 30 years in the pharmaceutical industry, specializing in discovering and developing new molecules for central nervous system disease treatment. A trained pharmacologist, he’s authored 25 scientific papers in prestigious international journals. Currently, as Initiator Pharma’s Senior VP for Research and Development, he advises private equity syndicates and owns Decision Insights.
During his 25-year tenure as Senior VP at Lundbeck, Allan led drug development from pre-clinical stages to NDA/EMA approval. He played a key role in bringing 6 products to market and overseeing over 75 due diligence processes, along with more than 7 asset and company acquisitions.
Board of Directors
Christian Hill Madsen – Chairman
Mr. Hill-Madsen has more than 25 years of experience working as a headhunter dedicated to the Life Science Industry in the Nordics, mastering the fine art of finding the best candidates for the right job, in all aspects of the healthcare solution program from Headhunting and Recruitment, Salesforce Optimization, Assessment to Organizational Development. Etc. Mr. Hill-Madsen is one of the few headhunters truly dedicated to the Life Science industry – from the single objective of wanting to be the best of what he does, working with his clients in the full employee life cycle to ensure that his clients always have the right person serving in the right position. Mr. Hill-Madsen is currently the founder and CEO of the Life Science headhunting firm, Hill-Consult, as well as being the founder and CEO of the Life Science advisory firm Nordicare Danmark, and Chairman of the Board of Directors of the Life Science venture holding company, NORDICUS Partners Corporation
Henrik Rouf – Member
Mr. Rouf has 30 years of experience in the global finance markets, working as an international financier, merchant banker and fund manager, respectively. Mr. Rouf advises and finances companies in many industries, including (though not limited to) software, semiconductors, blockchain, healthcare, medical devices, biotechnology, restaurant chains, apparel, cannabis, clean tech and advertising. Mr. Rouf has since 2004 been the President of PacificWave Partners Inc., a California-based merchant bank, and is also currently the CEO of the U.S. based Life Sciences holding company, Nordicus Partners Corporation. By being located and working in the United States for more than 30 years, Mr. Rouf has a vast network and extensive ties to especially the U.S., but also to Europe and Asia.
Henrik Keller – Member
Mr. Keller has more than four decades of experience in the corporate sector, in which he has a proven track record of delivering excellent performances. Mr. Keller possesses a unique set of strategical, managerial and sales capabilities, which has been key in the documented success he has delivered to the companies he has been, and are currently involved with, serving in various positions as Owner, General Manager, Sales Manager, Consultant/Advisor, Board Member, etc. Through his professional career, Mr. Keller has established a network which spans globally. Mr. Keller is currently the owner of the consultancy firm, HK-Consult, which advises companies within sales, marketing, customer service, partner search, strategy, etc. Mr. Keller further serves as the European representative for Blake Medical (CA); Scandinavian representative for Medical Spare Parts BV (NE). Mr. Keller also serves as Board Member for the U.S. based Life Sciences holding company, Nordicus Partners Corporation. From 2009 to 2012 he served as Board Member, Consultive Director and Partner at Athene Healthcare A/S; From 1998 to 2008 Mr. Keller was the General Manager at Huntleigh Healthcare A/S and General Manager for the Nordic Region at ArjoHuntleigh, after Huntleigh Healthcare A/S had a very successful merger with the Arjo Nordic companies.